Literature DB >> 30209647

Utility of intraocular endoscope for lacrimal canaliculi and sac examination.

Swati Singh1, Vikas Mittal2, Urvish Vashist2, Ruchi Mittal2, Purvasha Narang2.   

Abstract

PURPOSE: Intraocular endoscope was used as a dacryoendoscope, and its observations and performance in lacrimal drainage system (LDS) are reported.
METHODS: The Endo Optiks (Little Silver, New Jersey, USA), an intraocular endoscope (modified with customized sheath), was used for LDS visualization in ten normal adults and five patients with lacrimal disorders.
RESULTS: We were able to capture high-definition images of lacrimal canaliculi and sac in all normal adults. Smooth whitish canalicular mucosa with lumen could be appreciated in all normal individuals. Common canaliculus showed variable folds among individuals and reddish lacrimal sac mucosa could be appreciated with great details. In patients with canalicular obstruction, site of obstruction was presented as whitish gray area with no visible lumen, which could be opened up precisely with trephination. No false passage was formed in any of the cases. One of the cases had membranous canalicular obstruction, which was opened with probe itself. Nasolacrimal duct could not be examined due to the shorter length of the probe.
CONCLUSION: Intraocular endoscope can be used as high-resolution dacryoendoscope for visualization of lacrimal canaliculi and sac.

Entities:  

Keywords:  Dacryoendoscope; Endoptiks; Lacrimal canaliculi; Lacrimal sac

Mesh:

Year:  2018        PMID: 30209647     DOI: 10.1007/s10792-018-1017-9

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  2 in total

1.  Ocular surface squamous neoplasia at a tertiary eye facility, Southwestern Nigeria: a 10-year review.

Authors:  Oluyemi Fasina
Journal:  Int Ophthalmol       Date:  2021-05-20       Impact factor: 2.031

2.  Can preoperative lacrimal endoscopic evaluation change the paradigm of conventional lacrimal surgery?

Authors:  Sang Jae Lee; Kang Min Lee; Minwook Chang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-09-15       Impact factor: 3.117

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.